102
Participants
Start Date
November 13, 2017
Primary Completion Date
December 30, 2019
Study Completion Date
December 30, 2019
Mepolizumab
Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
GSK Investigational Site, Brussels
GSK Investigational Site, Leuven
GSK Investigational Site, Mar del Plata
GSK Investigational Site, Hanover
GSK Investigational Site, Toulouse
GSK Investigational Site, Fulda
GSK Investigational Site, Nantes
GSK Investigational Site, Guadalajara
GSK Investigational Site, Mayfield Heights
GSK Investigational Site, Cincinnati
GSK Investigational Site, Valencia
GSK Investigational Site, Florence
GSK Investigational Site, Rochester
GSK Investigational Site, Lille
GSK Investigational Site, Monterrey
GSK Investigational Site, Mannheim
GSK Investigational Site, Kirchheim unter Teck
GSK Investigational Site, Napoli
GSK Investigational Site, Murray
GSK Investigational Site, Villahermosa
GSK Investigational Site, La Jolla
GSK Investigational Site, Suresnes
GSK Investigational Site, Moscow
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Târgu Mureş
GSK Investigational Site, New Haven
GSK Investigational Site, Ciudad Autonoma de Buenos Aires
GSK Investigational Site, La Plata
GSK Investigational Site, Porto Alegre
GSK Investigational Site, Santo André - SP
GSK Investigational Site, Sorocaba
GSK Investigational Site, Krakow
GSK Investigational Site, Lodz
GSK Investigational Site, Bucharest
GSK Investigational Site, Barcelona
GSK Investigational Site, Leicester
Lead Sponsor
GlaxoSmithKline
INDUSTRY